| Schedule of Reconciliation to the Consolidated Net Loss |
The following table is representative of the significant
expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to
the consolidated net loss for the three months ended March 31, 2025 and 2024 is included at the bottom of the table below.
| |
|
For the Three Months
Ended March
31, |
|
| Significant segment expenses |
|
2025 |
|
|
2024 |
|
| General and administrative (1) |
|
$ |
1,696,425 |
|
|
$ |
1,897,719 |
|
| Pre-clinical research (1) |
|
|
61,993 |
|
|
|
430,384 |
|
| CMC (1) |
|
|
224,597 |
|
|
|
377,820 |
|
| Clinical development (1) |
|
|
1,434,804 |
|
|
|
826,117 |
|
| Depreciation and amortization |
|
|
161,708 |
|
|
|
162,257 |
|
| Share based compensation expense |
|
|
98,558 |
|
|
|
346,477 |
|
| Other segment items (2) |
|
|
2,094 |
|
|
|
- |
|
| Total operating and segment expenses |
|
|
3,680,179 |
|
|
|
4,040,774 |
|
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
76,867 |
|
|
|
26,716 |
|
| Realized foreign currency translation loss from dissolution of subsidiaries |
|
|
(7,171 |
) |
|
|
- |
|
| Interest and dividends, net |
|
|
47,245 |
|
|
|
153,218 |
|
| Segment and consolidated net loss |
|
$ |
3,563,238 |
|
|
$ |
3,860,840 |
|
|
(1) |
includes personnel costs and excludes
share-based compensation expense |
|
(2) |
includes loss from sale of assets,
and loss on asset write offs |
|